NZ735735B2 - Gene therapy to improve vision - Google Patents
Gene therapy to improve vision Download PDFInfo
- Publication number
- NZ735735B2 NZ735735B2 NZ735735A NZ73573516A NZ735735B2 NZ 735735 B2 NZ735735 B2 NZ 735735B2 NZ 735735 A NZ735735 A NZ 735735A NZ 73573516 A NZ73573516 A NZ 73573516A NZ 735735 B2 NZ735735 B2 NZ 735735B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- aav
- rod
- light
- aav vector
- photoreceptor
- Prior art date
Links
- 230000004438 eyesight Effects 0.000 title abstract description 26
- 238000001415 gene therapy Methods 0.000 title abstract description 7
- 101710035830 RGS9BP Proteins 0.000 claims abstract description 43
- 210000000234 Capsid Anatomy 0.000 claims abstract description 38
- 210000000880 Retinal Rod Photoreceptor Cells Anatomy 0.000 claims abstract description 34
- 230000001965 increased Effects 0.000 claims abstract description 24
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 13
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 13
- 230000011664 signaling Effects 0.000 claims abstract description 12
- 210000000964 Retinal Cone Photoreceptor Cells Anatomy 0.000 claims abstract description 11
- 230000000051 modifying Effects 0.000 claims abstract description 10
- 230000004064 dysfunction Effects 0.000 claims abstract description 7
- 210000000608 Photoreceptor Cells Anatomy 0.000 claims abstract description 6
- 102100016089 RGS9BP Human genes 0.000 claims abstract description 5
- 230000014509 gene expression Effects 0.000 claims description 51
- 210000001525 Retina Anatomy 0.000 claims description 19
- 208000002780 Macular Degeneration Diseases 0.000 claims description 15
- 238000005286 illumination Methods 0.000 claims description 11
- 206010064930 Age-related macular degeneration Diseases 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 241000432074 Adeno-associated virus Species 0.000 claims description 4
- 206010010050 Colour blindness Diseases 0.000 claims description 4
- 102100000433 PDE6B Human genes 0.000 claims description 4
- 101700018163 PDE6B Proteins 0.000 claims description 4
- 201000000761 achromatopsia Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000014091 Neural retina-specific leucine zipper protein Human genes 0.000 claims description 3
- 108050003956 Neural retina-specific leucine zipper protein Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 2
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 2
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims description 2
- 201000008615 cone dystrophy Diseases 0.000 claims description 2
- 230000004377 improving vision Effects 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 230000004310 photopic vision Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001508 Eye Anatomy 0.000 description 92
- 230000004044 response Effects 0.000 description 52
- 210000004027 cells Anatomy 0.000 description 50
- 230000003612 virological Effects 0.000 description 43
- 241000700605 Viruses Species 0.000 description 25
- 230000002018 overexpression Effects 0.000 description 22
- 239000002245 particle Substances 0.000 description 22
- 230000035945 sensitivity Effects 0.000 description 20
- 239000007924 injection Substances 0.000 description 19
- 230000001404 mediated Effects 0.000 description 19
- 230000002207 retinal Effects 0.000 description 18
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 17
- 235000020945 retinal Nutrition 0.000 description 17
- 239000011604 retinal Substances 0.000 description 17
- 102000004330 Rhodopsin Human genes 0.000 description 16
- 108090000820 Rhodopsin Proteins 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000000007 visual effect Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- 238000004806 packaging method and process Methods 0.000 description 13
- 238000011084 recovery Methods 0.000 description 13
- 102000004040 Capsid Proteins Human genes 0.000 description 12
- 108090000565 Capsid Proteins Proteins 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 108091008017 photoreceptors Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 102100008005 GPR180 Human genes 0.000 description 9
- 101710028548 GPR180 Proteins 0.000 description 9
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 9
- 108091006093 GTPases Proteins 0.000 description 9
- 102100000956 RGS9 Human genes 0.000 description 9
- 101700051004 RGS9 Proteins 0.000 description 9
- 108091006028 chimera Proteins 0.000 description 9
- 210000001519 tissues Anatomy 0.000 description 9
- 210000003994 Retinal Ganglion Cells Anatomy 0.000 description 8
- 230000005540 biological transmission Effects 0.000 description 8
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 8
- 230000016732 phototransduction Effects 0.000 description 8
- 108060002031 CNGA3 Proteins 0.000 description 7
- 230000003750 conditioning Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002068 genetic Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229920002676 Complementary DNA Polymers 0.000 description 6
- 108090001123 antibodies Proteins 0.000 description 6
- 102000004965 antibodies Human genes 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 238000004061 bleaching Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000002459 sustained Effects 0.000 description 6
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 5
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 5
- 101700055371 ERG Proteins 0.000 description 5
- 101700085508 KCNH2 Proteins 0.000 description 5
- 101700011826 KCNH6 Proteins 0.000 description 5
- 210000004379 Membranes Anatomy 0.000 description 5
- 210000003583 Retinal Pigment Epithelium Anatomy 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 108091005938 enhanced green fluorescent protein Proteins 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 102100012548 CNGA3 Human genes 0.000 description 4
- 229920001405 Coding region Polymers 0.000 description 4
- 210000004087 Cornea Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000000763 evoked Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 210000002592 gangliocyte Anatomy 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 230000010415 tropism Effects 0.000 description 4
- 230000004304 visual acuity Effects 0.000 description 4
- 230000016776 visual perception Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 102100000434 PDE6C Human genes 0.000 description 3
- 101700086724 PDE6C Proteins 0.000 description 3
- 210000000063 Presynaptic Terminals Anatomy 0.000 description 3
- 210000001747 Pupil Anatomy 0.000 description 3
- 229920000970 Repeated sequence (DNA) Polymers 0.000 description 3
- 239000008156 Ringer's lactate solution Substances 0.000 description 3
- 210000000225 Synapses Anatomy 0.000 description 3
- 230000001058 adult Effects 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 201000004569 blindness Diseases 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 230000026269 optomotor response Effects 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 238000009738 saturating Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- NCYCYZXNIZJOKI-MKOSUFFBSA-N 9-cis-retinal Chemical compound O=C/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-MKOSUFFBSA-N 0.000 description 2
- 102100004996 ATP12A Human genes 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- 239000012112 Alexa Fluor 633 Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 210000000695 Crystalline Lens Anatomy 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N DATI Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 210000003128 Head Anatomy 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000764238 Isis Species 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000003200 Peritoneal Cavity Anatomy 0.000 description 2
- 108010083204 Proton Pumps Proteins 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- 206010047518 Vision disease Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003444 anaesthetic Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 230000002490 cerebral Effects 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000004300 dark adaptation Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000004301 light adaptation Effects 0.000 description 2
- 230000004298 light response Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000003334 potential Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004243 retinal function Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229960004791 tropicamide Drugs 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100001692 ARR3 Human genes 0.000 description 1
- 101700064490 ARR3 Proteins 0.000 description 1
- 240000001606 Adenanthera pavonina Species 0.000 description 1
- 235000011470 Adenanthera pavonina Nutrition 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241000958487 Adeno-associated virus 3B Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 210000000411 Amacrine Cells Anatomy 0.000 description 1
- 241001402987 Arracacha virus B Species 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 210000003050 Axons Anatomy 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N Bisbenzimide Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 210000003161 Choroid Anatomy 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 108009000097 DNA Replication Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 210000001163 Endosomes Anatomy 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 229940109526 Ery Drugs 0.000 description 1
- 208000009745 Eye Disease Diseases 0.000 description 1
- 108091006011 G proteins Proteins 0.000 description 1
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 1
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108010083687 Ion Pumps Proteins 0.000 description 1
- 102000006391 Ion Pumps Human genes 0.000 description 1
- 108091006586 Ion Transporter Proteins 0.000 description 1
- 102000037246 Ion Transporter Human genes 0.000 description 1
- 210000000554 Iris Anatomy 0.000 description 1
- 210000001847 Jaw Anatomy 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000539716 Mea Species 0.000 description 1
- 229960004882 Medetomidine Hydrochloride Drugs 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N Phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 Phenylephrine Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000002092 Prolonged Electroretinal Response Suppression Diseases 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 240000004350 Prunus spinosa Species 0.000 description 1
- 235000010829 Prunus spinosa Nutrition 0.000 description 1
- 101710002981 RAD51B Proteins 0.000 description 1
- 101700085616 RHAG Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 229960003876 Ranibizumab Drugs 0.000 description 1
- 108010062724 Ranibizumab Proteins 0.000 description 1
- 101700006422 Rep40 Proteins 0.000 description 1
- 101700003689 Rep52 Proteins 0.000 description 1
- 101700006973 Rep68 Proteins 0.000 description 1
- 101700082620 Rep78 Proteins 0.000 description 1
- 210000003786 Sclera Anatomy 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 235000018185 birch Nutrition 0.000 description 1
- 235000018212 birch Nutrition 0.000 description 1
- 201000011466 bradyopsia Diseases 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2S)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000023077 detection of light stimulus Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229920005994 diacetyl cellulose Polymers 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl β-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000000485 pigmenting Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229910052904 quartz Inorganic materials 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 201000007737 retinal degeneration Diseases 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 210000002508 rod bipolar cell Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000000946 synaptic Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The invention relates to the use of gene therapy vectors to improve vision by introducing into healthy rod photoreceptor cells of a patient suffering from cone photoreceptor dysfunction and/or degeneration a nucleic acid encoding a gene product that is light-sensitive and/or that modulates endogenous light-sensitive signalling in a photoreceptor cell, such that the range of light intensities to which the rod photoreceptor responds is extended and/or the speed at which the rod photoreceptor responds to light is increased. In a particular embodiment, the gene product is ArchT or R9AP, and the capsid of the vector is derived from AAV8. s light-sensitive signalling in a photoreceptor cell, such that the range of light intensities to which the rod photoreceptor responds is extended and/or the speed at which the rod photoreceptor responds to light is increased. In a particular embodiment, the gene product is ArchT or R9AP, and the capsid of the vector is derived from AAV8.
Description
GENE THERAPY TO IMPROVE VISION
FIELD OF THE INVENTION
The present invention relates to the use of gene therapy vectors to improve vision in
patients.
BACKGROUND OF THE INVENTION
In many mammalian species including mice and humans, the number of rod
photoreceptors that mediate vision under dim light outnumbers greatly that of cone
photoreceptors (Curcio et al, 2000). However, in an industrialised world where
illumination allows cones to operate throughout the day, rod-mediated vision is less
important. Many patients with absent rod function from birth are identified only
incidentally and, in fact, cannot recognize their abnormal vision (Dryj a, 2000). On the
contrary, when cone ction is present, patients are always symptomatic and often
suffer visual handicap dependent on the degree of their cone ction. In some
conditions, however, only (or ) the cones are lost or dysfunctional and rods
remain relatively preserved. For example, achromatopsia is a severe hereditary retinal
phy with a complete absence of cone function from birth but, presumably, with a
normal rod fiinction (Hess et al, 1986; Nishiguchi et al, 2005). Mutations in multiple
genes including CNGA3 (Kohl et al 1998), and PDE6C (Chang et al, 2009, Thiadens et
al, 2009) have been associated with the disease. Each of the e causing genes
encodes an essential component of the cone phototransduction cascade that translates
light into an electric signal by causing hyperpolarization of the photoreceptor cell. In
age d macular degeneration (AMD), visual impairment is caused primarily by
degeneration of the cone-rich fovea in the central macula. Thus ts lose central
vision and acuity, but often have relatively well preserved peripheral macula and thus
have some useful residual vision that is d by the paucity of cones outside the
fovea.
Rods are highly sensitive to light, which s them to perceive a small amount of
light in dim conditions. Cones, on the contrary, are less sensitive, but are capable of
processing large amounts of light and uously convey visual signals in daylight.
This fiinctional difference is, in part, due to the efficiency of the deactivation ery
of photo-signalling, the GTPase complex composed of RGS9, R9AP (also known as
RGS9BP), and G85. RGS9 is the catalytic component that hydrolyses the GTP coupled
to the G-protein, whereas R9AP and G135 are the essential constitutive ts (Burns
et al, 2009; Burns et al, 2010). Importantly, R9AP tethers the complex to the disc
membrane at the photoreceptor outer segment where the phototransduction signalling
also takes place (Baseler et al, 2002). Expression of R9AP determines the level of
GTPase complex such that any RGS9 produced in excess of R9AP is likely quickly
degraded (Martyemyanov et a1, 2009). Over-expression of R9AP in the murine rods is
sufficient to increase the GTPase activity and to substantially speed their deactivation
cs as evidenced by the single cell recordings (Krispel et al, 2006). In the cones,
the RGS9 expression has been estimated to be ~10-fold higher than that of the rods
(Cowan et a1, 1998; Zhang et al, 2003). This provides a basis for the ability ofthe cones
to recover quickly from light exposure and thus maintain functional to continuous light
stimulus. It also allows cones to respond to more rapid stimulation. Indeed, clinically,
patients with delayed deactivation of phototransduction cascade caused by genetic
defects in RGS9 or R9AP, or bradyopsia, have a nd impairment ofcone-mediated
vision including day blindness and d y to see moving objects Nishiguchi et
a1, 2004; Michaelides et al, 2010). ile, the rod-mediated vision is less ed
by the same mutation.
Some macular ration conditions, such as age-related macular degeneration
(AND) and inherited macular degeneration conditions also exhibit cone dysfunction
but normal or less impaired rod function. Macular ration is the leading cause of
blindness in the developed world and as its prevalence quadruples in each decade of
life the instance of AMD is expected to rise in the coming years as life expectancy
increases. Drugs for the treatment of AMD already account for over 1% of the entire
drugs budget of the UK’ s al Health e. While patients with advanced AMD
can be trained to fixate extra-foveally, the low refresh rate and the low bleaching
threshold of rod cells limits the quality of resulting vision.
SUMMARY OF THE INVENTION
Using mice with absent cone function, we have demonstrated that AAV-mediated overexpression
of Rgs9-anchor protein (R9AP), a critical component of GTPase complex
that mediates the deactivation of phototransduction cascade, results in desensitization
and “photopic shift” ofthe rod-driven oretinogram. The treatment enables the rods
to respond to brighter light (up to ~20 log) than the ted cells at the expense of
scotopic (lower light level) fiinction. Multi-electrode array measurements using the
treated retinas showed that the retinal ganglion cells also reflected the “photopic shift”
of the rods, by exhibiting graded responses at ic light levels. Contrast sensitivity
function measured by quantifying the racking movements in response to rotating
sinusoidal gs showed an ement of the sensitivity by up to 25-fold under
room light conditions and faster response to repeated stimuli. Furthermore, biochemical
measurement of bleachable rhodopsin levels in these mice indicated that the visual
cycle was not limiting rod function.
We have also expressed a fast light-driven proton pump, ArchT (Han et al, 2011) in rod
photoreceptors. AAV8 particles carrying ArchT-EGFP under control of the Rhodopsin
promoter (Rho) were ed subretinally in adult mice. Expression of Rho-ArchT-
EGFP was limited to the membrane of rod photoreceptors. Expression of ArchT
allowed extremely rapid light responses, while the intrinsic rod response was preserved
and was comparable to that observed in non—transduced rod photoreceptors. Overall,
ArchT expression did not alter the y of rod photoreceptors to respond to scotopic
stimuli, but it did confer an additional ability to respond with rapid non-bleaching
responses to higher levels of illumination. We also found that the transduced rods were
able reliably to sustain this fast ‘cone-like’ transmission, in that ArchT-expressing rods
drove sustained retinal on cell (RGC) spiking at high light intensities and at
frequencies approaching those of cone photoreceptors, Expression of Rho-ArchT-
EGFP in CNGA3-/- and PDE6C-/- mice lacking cone-mediated vision also extended
the sensitivity of these mice to bright light stimuli and conferred fast vision on these
mice. The maximal frequency of stimuli that ArchT-expressing mice could follow was
similar to that of cone photoreceptors.
Together, these results show that, after transduction of y rod photoreceptors with
genes encoding either light sensitive proteins characteristic of cones or genes encoding
molecules that increase the speed of the endogenous rod signalling mechanism, rods
behave more like cones and hence can compensate for cone ction. This has
implications for the treatment of a number of vision disorders in which cone function
is reduced, but at least some healthy rods remain. This contrasts with previous
ches (Busskamp et al, 2010; US Patent Publication No. 2012258530) in which
the goal was to restore lost on in cones. Altering function in rods in the manner
of the present invention is advantageous in that conditions in which cones are
dysfunctional but can be repaired (for example in the early stages of retinal
ration when photoreceptor function is lost but the photoreceptor-to-bipolar
synapse may be intact) are rare, whereas ions in which cone dysfunction is more
severe or advanced and cannot be repaired or where cones are lost entirely, but yet at
least some healthy rod photoreceptors remain, are common (see above). Furthermore,
this ion enables the on of a ‘pseudo-fovea’, a small patch of cone-like rods
that will improve vision in conditions in which foveal cones have been lost or are
dysfunctional.
The ion therefore provides a vector sing a nucleic acid encoding a gene
product that is light-sensitive and/or that modulates endogenous light-sensitive
signalling in a photoreceptor cell, for use in a method of improving vision in a patient
with cone photoreceptor dysfunction and/or degeneration by introduction of said
nucleic acid into healthy rod photoreceptors in the retina of the patient and expression
of said gene product therein, such that the range of light intensities to which the rod
photoreceptor responds is extended and/or the speed at which the rod photoreceptor
responds to light is increased.
The invention also provides a vector as defined above, a host cell comprising said vector
and methods of treatment carried out with such a .
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1: Expression of ArchT in rod photoreceptors leads to fast light-driven
currents.
(a), top panels: ediated transduction of ArchT—EGFP (green, see left )
under control of the Rhodopsin promoter. No overlap is observed with cones (purple:
Cone arrestin, see middle panels, white: DAPI, see right panels). Lower panels:
specificity of expression can also be observed at the level of synapses. (b) ArchT-EGFP
is localized to the ne of rod photoreceptors, including inner and outersegments.
(c) Quantification of fluorescence in EGFP-expressing rod als (green, left
peak) and Cone in positive cone terminals (purple, right peak) shows two ct
bands corresponding to the sub-layer where rod and cone synapses localize respectively
(n=22). (d) Single-cell recordings from the cell bodies of ArchT-expressing rod
photoreceptors. The currents mediated by the intrinsic rod photo-trandsuction (upper
trace) in response to 10 ms 530-nm light pulses (green, see vertical bars) were
preserved. The ArchT-generated currents were faster (lower . Scale bars: (a) upper
panels: 50 um, (a) lower panels and (b): 10 um.
Figure 2: ArchT-expression drives high-frequency responses in rods and fast
transmission to Retinal Ganglion Cells.
2016/050419
(a) Intrinsic rod light-evoked currents in uninjected C57BL6 retinas. (b) ArchT-
mediated currents are able to follow much higher stimulation ncies. (c)
Responses are time-locked to stimulus presentation (green vertical bars). ((1) ArchT-
expressing rods respond to frequency stimulation up to 80 Hz t faltering, whereas
intrinsic rod responses drop off at ~20 Hz. (e) y data showing that ArchT
expression does not alter the intrinsic response of rod photoreceptors, while ArchT
responses begin at brighter light levels. (f) Multi-electrode array recordings from
PDE6C-/- ArchT-expressing retinas. sic rod responses failed to elicit reliable
Retinal Ganglion Cell spiking above 20 Hz.. On the contrary, ArchT-mediated rod
activation drove fast g of Retinal Ganglion Cells to levels able to cone
photoreceptors.
Figure 3: ArchT-mediated activation of rods drives behavioural response for fast
high light intensity-stimuli.
(a) Top panels: schematic for fear conditioning behaviour. Briefly, a visual stimulus
was paired with a shock. 24 hours later freezing behaviour was tested in a new context.
Bottom : uninjected CNGA3'/' and /' mice failed to learn the task (left
sets of bars in each graph). However, ArchT expression successfully drove freezing
behaviour in mice (right sets of bars in each graph). (b) Optomotor testing. ArchT-
expressing mice are able to follow stimuli at frequencies comparable to those reliably
followed by cones.
A. Figure 4: diated R9AP over-expression in rods and accelerated a-
wave deactivation in /- mice.Increased RGS9 expression in a Cnga3-/- eye
treated with rRAAV2/8.Rho.mR9ap. Over-expression of R9AP results in increased
immunoreactivity toward RGS9 (red) throughout the photoreceptor layer in the treated
eye (left) compared to the untreated (right). Western blot shows increased expression
of RGS9 both in the retina and retinal pigment epithelium (RPE) in the eye over-
expressing R9AP (bottom). A small amount of RGS9 protein was also detected in the
WO 35457
RPE of the treated eye. This may reflect “spill over” of the excessive protein contained
within the phagocytosed disc membrane. Scale bar tes 25 um.
B. Increased speed of a-wave amplitude ry in the Cnga3-/— eye treated with
rAAV2/8.Rho.mR9ap and rAAV2/8.CMV.mR9ap. Representative ERG tracings for
the probe flash (black traces, see traces with peak in the middle of the timecourse) and
for the 2nd flash (red traces) presented at inter-stimulus interval (181) of2 s from
the treated (top) and untreated (bottom) eyes from the same animal. Note that a second
flash yields small a-wave (arrow) is clearly visible in the treated eye, whereas a-wave
is not visible (arrow) in the untreated fellow eye. A plot of a-wave recovery at various
ISIS in the treated and untreated eyes. The eyes injected with rAAV2/8.CMV.mR9ap
(n = 5) or rAAV2/8.Rho.mR9ap (n = 7) have faster recovery kinetics than the ted
eye (11 = 5) that is most visible with shorter ISIs. The data is presented as average ::
standard error of the mean. OE: over-expression.
Figure 5: Gain of photopic function by rods h over-expression of R9AP in
Cnga3-/- mice.
A. Elevation of se threshold and photopic shift of 6H2 ERGs through over-
expression of R9AP in rods of Cnga3-/- mice. Representative 6H2 ERG traces from a
Cnga3-/— mouse in which one eye was treated with rAAV2/8.CMV.mR9ap and the other
eye was left untreated (top panel). ERG traces are aligned from responses against the
dimmest flash (-6.0 log eds/ml) to the brightest flash (2.0 log eds/ml, bottom) from
the top to the bottom at 0.5 log.cd.s/m2 step. Note that the lower threshold flash intensity
at which the responses emerge is increased, which is coupled with elevated response
threshold to brighter . This results in a “photopic shift” of the retinal function in
the eye treated with rAAV2/8.CMV.mR9ap. Summary of 6H2 ERG results
demonstrating photopic shift of the retinal function following treatment with
rAAV2/8.CMV.mR9ap or rAAV2/8.Rho.mR9ap m panel). ERG ses from
Gnat1-/- mice nt in rod function represents cone-mediated function. Meanwhile,
responses from C57BL6 mice are derived from both rod and cone photoreceptors. The
2016/050419
data is presented as % amplitude relative to the maximal response and is presented as
average :: standard error of the mean. ERGs were recorded from Cnga3-/- mice treated
with rAAV2/8.CMV.mR9ap (Cnga3 -/- CMV.R9ap; N = 8), Cnga3-/- mice treated with
rAAV2/8.Rho.mR9ap (Cnga3-/- Rho.R9ap; N = 6), Cnga3-/— mice untreated (Cnga3-
/- Untreated; N = 8), Gnat1-/- mice ted (Gnatl-/- ted; N = 6), and C57BL6
mice untreated (C57BL6 Untreated; N = 6)
B. sed retinal responses to long flashes in the Cnga3-/— eye treated with
rAAV2/8.CMV.mR9ap. Open rectangle denotes the duration of the flash. Note that in
the eye treated with rAAV2/8CMVmR9ap, responses are detectable with increased
duration of light stimulus. Conversely, the untreated contralateral eye shows little or no
response when recorded simultaneously at identical conditions.
C. Gain of retinal on under photopic conditions in the Cnga3-/- eyes treated
with rAAV2/8.CMV.mR9ap. Note that the treated eye shows responses under photopic
ing ions (white background light of 20 cd/mz) whereas the untreated
contralateral eye recorded simultaneously remained unresponsive.
Figure 6: Efficient transmission of the altered photoreceptor signal to the bipolar
cells in the eyes over-expressing R9AP
A. Representative ERG . ERGs were recorded after rAAV2/8.CMV.mR9ap
injection (red trace, lower trace) in a Cnga3-/— mouse using a saturating flash (1.9 log
cd.s/m2). The contralateral eye served as an untreated control (black trace, upper trace).
B. d activation of the bipolar cells to a flash. A-wave and b-wave implicit
times were measured from an ERG response to a saturating flash (1.9 log cd.s/m2) in
the treated and untreated eyes.
C. Intensity se curve for a—wave and b-wave amplitudes recorded from
Cnga3-/- mice (N=5) with one eye treated with rAAV2/8.CMV.mR9ap (red curves)
and the other eye left untreated (black curves). All data are presented as average ::
standard error of the mean. OE: over-expression.
2016/050419
Figure 7: A gain of sustainable visual perception following R9AP over-expression
in Cnga3-/- mice.
A. Improved contrast sensitivity function measured by optokinetic responses. In
the Cnga3-/- mice treated with 8.Rho.mR9ap in the left eye, the contrast
sensitivity function (CSF) was differentially measured for clockwise (representing
treated left eye) and counter-clockwise (representing untreated right eye) head tracking
movements against sinusoidal gratings. The CSF for the treated eyes (red curve) was
better than that for the untreated eyes (blue , which was similar to that for the
hed Cnga3 -/- mice (black curve; average ofboth eyes). Note that the CSF for the
treated eye was equivalent to, if not slightly better, to that for untouched wild—type
controls (green; average of both eyes). N= 5 for all groups. All data are ted as
average it standard error of the mean. OE: xpression.
B. Sustained rhodopsin levels after prolonged exposure to Optomotry test. A
representative recording of optical absorption of ocular sample using ng
spectrophotometer (left panel inside the green dashed box). Subtracting the absorption
of ocular s measured after (blue trace, top trace between 300 and 400nm) from
before (red trace) complete photobleaching showed )tmin peaking at ~3 80 nm
corresponding to released photoproducts coupled with kmax peaking at ~500 nm
representing the amount of bleachable rhodopsin in the sample (right panel inside the
green dashed box). Rhodopsin bleaching speed was assessed by measuring the
difference um (kmax) in the fully dilated eyes treated or untreated with
rAAV2/8.Rho.mR9ap in Cnga3 -/- mice after 5 minutes’ exposure to 7.0 mW white light
(bottom left; average :: standard error of the mean). Rhodopsin levels was measured
also after exposure of the Cnga3-/— mice to Optomotry test for up to 120 s (right
bottom, N=3 for each time point) following unilateral injection of
rAAV2/8.Rho.mR9ap. The grey area tes rhodopsin levels (mean i standard
deviation) recorded from untouched Cnga3-/— mice (N=8) after an overnight dark-
adaptation. Dotted line tes the average. Note that the level of rhodopsin remains
stable for at least 2 hours in both the eyes treated with rAAV2/8.Rho.mR9ap and the
ted eyes ofCnga3-/— mice. Data with error bars were presented as mean ::standard
error of the mean.
Figure 8: Over-expression of R9AP increases the recovery speed of rod
photoresponse in /- mice.
The time constant (c) for 50% recovery of a-wave amplitude was reduced by ~50% in
the Pde6c-/- eyes ed with rAAV2/8.CMV.mR9ap (o = ~ 5.75 sec) compared to
the untreated contralateral eyes (6 = ~ 11.46 sec) consistent with accelerated
deactivation of phototransduction following the treatment. N = 6. Data with error bars
were displayed as mean ::standard error of the mean.
Figure 9: Over-expression of R9AP s in “photopic shift” of the intensity-
response curve in Pde6c-/- mice.
The eyes injected with rAAV2/8.CMV.mR9ap showed photopic shift ofthe 6 Hz ERG
responses to ental flash intensities compared to the untreated contralateral eyes
in Pde6c-/- mice (N = 6). The data is presented as % amplitude relative to maximal
response and is displayed as e i standard error of the mean.
Figure 10: Sustained effect of R9AP over-expression without clear evidence of
retinal ration at 5 months post-injection of rAAV2/8.CMV.mR9ap in
Cnga3-/- mice.
Response profile normalized against maximum amplitude confirmed the presence of
“photopic shift” of the intensity-response curve to 6Hz flashes (top). The same data
without normalization showed no evidence of reduction in amplitudes in the treated eye
m). N = 5. The data is presented as average :: standard error of the mean.
Figure 11: Treatment of wild-type mice with rAAV2/8.Rho.mR9ap showed no
obvious effect on 6 Hz ERG ity-response curve.
The eyes treated with rAAV2/8.Rho.mR9ap showed no shift in 6 Hz ERG intensity-
response curve compared to that for the untreated contralateral eyes in C57BL6 mice
(N = 5). The data is presented as average :: standard error of the mean.
Figure 12: No gain of visual perception following R9AP xpression in
C57BL6 mice.
In the C57BL6 mice treated with rAAV2/8.Rho.mR9ap only in the left eye, the contrast
sensitivity function (CSF) was differentially ed for ise (representing
treated left eye) and counter-clockwise (representing untreated right eye) head tracking
movements to rotating sinusoidal gratings. The CSF for both the treated eyes (pink
curve) and the untreated eyes (light blue curve) showed similar results, which was
similar to that for the untouched C57BL6 mice (green curve; average ofboth eyes). N=
for all groups. All data are presented as average :: standard error of the mean. OE:
over-expression.
DETAILED DESCRIPTION OF THE INVENTION
A vector of the invention comprises a c acid whose expression to e a gene
product, typically a protein, which will effect treatment of an ocular condition as
described herein, operably linked to a promoter to form an expression cassette.
Nucleic Acids and Gene Products
A vector ofthe ion comprises a nucleic acid encoding a gene product that is light-
sensitive and/or that modulates endogenous light-sensitive signalling in a photoreceptor
cell and makes a rod transduced with the nucleic acid of the invention behave more like
a cone by extending the range light intensities to which the rod eceptor responds
is and/or increasing the speed at which the rod photoreceptor responds to light. Thus,
the n may itself be directly light-sensitive, e.g. it may change ne
conductance in rods in a way that results in hyperpolarisation (outward t flow)
upon light stimulation. Such proteins will for example be light-sensitive or light-gated
G—coupled membrane proteins, ion channels, ion pumps or ion transporters. Preferred
light-sensitive proteins include ArchT, Jaws (cruxhalorhodopsin) (Chuong et al, 2014)
and iClC2. atively, the protein may itself not be directly light-sensitive but may
indirectly modulate endogenous light-sensitive signalling in a rod photoreceptor cell.
Examples of such proteins are members of the RG89 complex, notably R9AP (also
known as RGS9BP), and G135. In the ative, the nucleic acid may encode any other
gene product that increases the speed of the endogenous rod signalling mechanism. In
all of these cases, the sequence may encode a wild-type protein or a mutant or variant
or truncated version that retains the activity of the wild—type protein. The nucleic acid
may also be codon-optimised for expression in the target cell type.
Following expression of the gene t, rods will show stronger and/or faster
modulation to light stimuli than non—transduced rods, at higher than usual intensities.
Examples e improved modulation strength and/or faster activation/inactivation
kinetics. Rods transduced according to the invention will therefore react more strongly
and/or quickly to illumination in the mesopic and/or photopic range than non-
transduced rods. Preferably, the response of the rods to scotopic illumination conditions
is cted or not substantially affected, ie the rods gain the ability to respond strongly
and/or quickly to brighter light without losing the ability to d to dim light.
Promoters and other regulatory elements
In the expression construct, the nucleic acid encoding the gene t is typically
operably linked to a promoter. The promoter may be constitutive but will preferably
be a photoreceptor-specific or photoreceptor-preferred promoter, more preferably a
rod—specific or rod-preferred promoter such as a Rhodopsin (Rho), Neural retina-
specific leucine zipper protein (NRL) or Phosphodiesterase 6B (PDE6B) promoter. The
promoter region incorporated into the expression cassette may be of any length as long
as it is effective to drive sion of the gene product, preferably photoreceptor-
specific or photoreceptor-preferred expression or rod-specifrc or rod- preferred
expression.
By a eceptor-specific promoter, is meant a promoter that drives expression only
or substantially only in photoreceptors, e.g. one that drives expression at least a
hundred-fold more strongly in photoreceptors than in any other cell type. By a rod-
specifrc promoter, is meant a promoter that drives expression only or ntially only
in photoreceptors, e. g. one that drives sion at least a hundred-fold more strongly
in photoreceptors than in any other cell type, including cones. By a photoreceptor-
preferred promoter, is meant a promoter that expresses preferentially in photoreceptors
but may also drive expression to some extent in other s, e.g. one that drives
expression at least two-fold, at least five-fold, at least ten-fold, at least 20-fold, or at
least d more strongly in photoreceptors than in any other cell type. By a rod-
preferred promoter, is meant a promoter that drives sion preferentially in
photoreceptors but may also drive expression to some extent in other tissues, e.g. one
that drives expression at least two-fold, at least five-fold, at least ten-fold, at least 20-
fold, or at least 50-fold more strongly in photoreceptors than in any other cell type.
including cones.
One or more other regulatory ts, such as enhancers, may also be present as well
as the promoter.
Vectors
A vector of the invention may be of any type, for example it may be a plasmid vector
or a minicircle DNA.
Typically, vectors of the invention are however viral vectors. The viral vector may for
example be based on the herpes x virus, adenovirus or lentivirus. The viral vector
may be an adeno-associated virus (AAV) vector or a derivative thereof. The viral vector
derivative may be a chimeric, shuffled or capsid modified tive.
The viral vector may comprise an AAV genome from a naturally derived serotype,
isolate or clade of AAV. The serotype may for example be AAV2, AAVS or AAV8.
The efficacy of gene y is, in general, dependent upon te and efficient
delivery ofthe donated DNA. This process is usually mediated by viral vectors. Adeno-
associated viruses (AAV), a member of the parvovirus family, are commonly used in
gene therapy. Wild-type AAV, containing viral genes, insert their genomic material into
chromosome 19 of the host cell. The AAV single-stranded DNA genome comprises
two ed terminal s (ITRs) and two open reading frames, containing structural
(cap) and packaging (rep) genes.
For therapeutic purposes, the only sequences required in cis, in addition to the
therapeutic gene, are the ITRs. The AAV virus is therefore modified: the viral genes
are removed from the genome, producing recombinant AAV (rAAV). This contains
only the therapeutic gene, the two ITRs. The removal of the viral genes renders rAAV
incapable of actively inserting its genome into the host cell DNA. d, the rAAV
genomes fuse via the ITRs, forming circular, episomal structures, or insert into pre-
existing somal breaks. For viral production, the structural and packaging genes,
now removed from the rAAV, are supplied in trans, in the form of a helper plasmid.
AAV is a ularly attractive vector as it is lly non-pathogenic; the majority
people have been infected with this virus during their life with no adverse effects.
The immune privilege of ocular tissue, a result of anatomical barriers and
immunomodulatory s, renders the eye largely exempt from the adverse
immunological responses that can be triggered in other tissues by AAV (Taylor 2009).
AAV vectors are limited by a relatively small packaging ty of roughly 4.8kb and
a slow onset of expression following transduction. Despite these minor drawbacks,
AAV has become the most ly used viral vector for retinal gene therapy.
Most vector constructs are based on the AAV serotype 2 (AAV2). AAV2 binds to the
target cells Via the heparin sulphate proteoglycan receptor. The AAV2 genome, like
those of all AAV serotypes, can be enclosed in a number of different capsid proteins.
AAV2 can be ed in its natural AAV2 capsid (AAV2/2) or it can be pseudotyped
with other capsids (eg. AAV2 genome in AAVl capsid; AAV2/ 1, AAV2 genome in
AAV5 , AAV2/5 and AAV2 genome in AAV8 capsid, AAV2/8).
rAAV transduces cells via serotype specific receptor-mediated endocytosis. A major
factor influencing the cs of rAAV transgene expression is the rate of virus particle
uncoating within the endosome. This, in turn, depends upon the type of capsid enclosing
the genetic material (Ibid.). After uncoating the linear single-stranded rAAV genome is
stabilised by forming a -stranded molecule via de novo synthesis of a
complementary strand. The use of self-complementary DNA may bypass this stage by
producing double-stranded transgene DNA. Natkunaraj ah et al (2008) found that selfcomplementary
AAV2/8 gene expression was of faster onset and higher amplitude,
ed to single-stranded . Thus, by circumventing the time lag associated
with second-strand synthesis, gene expression levels are increased, when compared to
transgene expression from standard single-stranded ucts. Subsequent studies
investigating the effect of self-complementary DNA in other AAV pseudotypes (e. g.
AAV2/5) have produced similar results. One caveat to this technique is that, as AAV
has a packaging capacity of approximately 4.8kb, the self-complementary inant
genome must be appropriately sized (i.e. 2.3kb or less).
In addition to modifying packaging capacity, pseudotyping the AAV2 genome with
other AAV capsids can alter cell specificity and the cs of transgene expression.
AAV2/8 is reported to transduce photoreceptors more efficiently than either AAV2/2
or AAV2/5 (Natkunaraj ah et al. 2008).
The vector of the invention may therefore se an adeno-associated virus (AAV)
genome or a derivative thereof.
An AAV genome is a polynucleotide sequence which s functions needed for
production of an AAV viral particle. These functions include those operating in the
replication and packaging cycle for AAV in a host cell, including encapsidation of the
AAV genome into an AAV viral particle. Naturally occurring AAV viruses are
replication-deficient and rely on the ion of helper functions in trans for
completion of a replication and packaging cycle. Accordingly and with the onal
removal of the AAV rep and cap genes, the AAV genome ofthe vector ofthe invention
is ation-deficient.
The AAV genome may be in single-stranded form, either ve or negative-sense, or
alternatively in double-stranded form. The use of a double-stranded form allows bypass
ofthe DNA replication step in the target cell and so can accelerate transgene expression.
The AAV genome may be from any naturally derived serotype or isolate or clade of
AAV. As is known to the skilled person, AAV viruses occurring in nature may be
fied according to various biological systems.
ly, AAV viruses are referred to in terms of their serotype. A serotype
corresponds to a variant subspecies ofAAV which owing to its profile of expression of
capsid surface antigens has a distinctive reactivity which can be used to distinguish it
from other variant subspecies. Typically, a virus having a particular AAV serotype does
not efficiently cross-react with neutralising antibodies specific for any other AAV
serotype. AAV serotypes include AAVl, AAV2, AAV3, AAV4, AAV5, AAV6,
AAV7, AAV8, AAV9, AAVlO and AAVl 1, also recombinant serotypes, such as Rec2
and Rec3, ly identified from primate brain. In vectors of the invention, the
genome may be derived from any AAV serotype. The capsid may also be derived from
any AAV serotype. The genome and the capsid may be derived from the same serotype
or different serotypes.
In vectors ofthe invention, it is preferred that the genome is derived from AAV serotype
2 (AAV2), AAV serotype 4 (AAV4), AAV serotype 5 (AAVS) or AAV serotype 8
(AAV8). It is most preferred that the genome is derived from AAV2 but other serotypes
of particular interest for use in the invention include AAV4, AAVS and AAV8, which
efficiently transduce tissue in the eye, such as the retinal pigmented epithelium. It is
red that the capsid is derived from AAVS or AAV8, especially AAV8.
Reviews of AAV serotypes may be found in Choi et a1 (Curr Gene Ther. 2005; 5(3);
299—310) and Wu et al (Molecular Therapy. 2006, 14(3), 316-327). The ces of
AAV genomes or of elements of AAV genomes including ITR sequences, rep or cap
genes for use in the invention may be derived from the following accession numbers
for AAV whole genome sequences: Adeno-associated virus 1 NC_002077, AF063497 ;
Adeno-associated virus 2 NC_001401; Adeno-associated virus 3 729, Adeno-
associated virus 3B NC_001863; Adeno-associated virus 4 NC_001829; Adeno-
associated virus 5 Y18065, 16; Adeno-associated virus 6 NC_001862, Avian
AAV ATCC VR-865 AY186198, AY629583, NC_004828; Avian AAV strain DA-l
NC_006263, 83, Bovine AAV NC_005889, AY3 88617.
AAV viruses may also be referred to in terms of clades or . This refers to the
phylogenetic relationship of naturally derived AAV viruses, and typically to a
enetic group of AAV s which can be traced back to a common ancestor,
and includes all descendants thereof. onally, AAV viruses may be referred to in
terms of a specific isolate, i.e. a genetic isolate of a specific AAV virus found in nature.
The term genetic isolate describes a population of AAV Viruses which has undergone
limited genetic mixing with other naturally occurring AAV Viruses, thereby defining a
recognisably distinct population at a genetic level.
Examples of clades and isolates of AAV that may be used in the ion include:
Clade A: AAVl NC_002077, AFO63497, AAV6 NC_001862, Hu. 48 AY530611,
Hu 43 AY530606, Hu 44 AY530607, Hu 46 AY530609
Clade B: Hu. 19 84, Hu. 2O AY530586, Hu 23 AY530589, Hu22 AY530588,
Hu24 AY530590, Hu21 AY530587, Hu27 AY530592, Hu28 AY530593, Hu 29
AY530594, Hu63 AY530624, Hu64 AY530625, Hu13 AY530578, Hu56 AY530618,
Hu57 19, Hu49 AY530612, Hu58 AY530620, Hu34 AY530598, Hu35
AY530599, AAV2 NC_001401, Hu45 AY530608, Hu47 AY530610, Hu51
AY530613, Hu52 AY530614, Hu T41 AY695378, Hu S17 AY695376, Hu T88
AY695375, Hu T71 AY695374, Hu T70 AY695373, Hu T40 72, Hu T32
AY695371, Hu T17 AY695370, Hu LG15 AY695377,
Clade C: Hu9 29, HulO 76, Hull AY530577, Hu53 AY530615, Hu55
AY530617, Hu54 AY530616, Hu7 AY530628, Hu18 AY530583, Hu15 AY530580,
Hu16 AY530581, Hu25 AY530591, Hu60 AY530622, Ch5 AY243021, Hu3
AY530595, Hul AY530575, Hu4 AY530602 Hu2, AY530585, Hu61 23
Clade D: Rh62 AY530573, Rh48 61, Rh54 AY530567, Rh55 AY530568, Cy2
AY243020, AAV7 AF513851, Rh35 AY243000, Rh37 AY242998, Rh36 AY242999,
Cy6 AY243016, Cy4 AY243018, Cy3 AY243019, Cy5 AY243017, Rh13 AY243013
Clade E: Rh38 AY530558, Hu66 AY530626, Hu42 AY530605, Hu67 AY530627,
Hu40 AY530603, Hu41 AY530604, Hu37 AY530600, Rh40 AY530559, Rh2
AY243007, Bbl AY243023, Bb2 AY243022, Rth AY243015, Hu17 AY530582, Hu6
AY530621, Rh25 57, Pi2 AY530554, Pil AY530553, Pi3 AY530555, Rh57
AY530569, Rh50 AY530563, Rh49 AY530562, Hu39 AY530601, Rh58 AY530570,
Rh6l AY530572, Rh52 AY530565, Rh53 AY530566, RhSl AY530564, Rh64
AY530574, Rh43 AY530560, AAV8 AF513852, Rh8 AY242997, Rhl AY530556
Clade F: Hul4 (AAV9) AY530579, Hu3l AY530596, Hu32 AY530597, Clonal Isolate
AAVS Y18065, AF085716, AAV 3 NC_001729, AAV 3B NC_001863, AAV4
829, Rh34 AY243001, Rh33 AY243002, Rh32 AY243003/
The skilled person can select an appropriate serotype, clade, clone or e of AAV
for use in the present invention on the basis of their common general knowledge. It
should be understood however that the invention also encompasses use of an AAV
genome of other serotypes that may not yet have been identified or characterised. The
AAV serotype determines the tissue specificity of infection (or tropism) of an AAV
virus. Accordingly, preferred AAV serotypes for use in AAV viruses administered to
patients in accordance with the invention are those which have natural tropism for or a
high efficiency of ion of rod photoreceptors.
Typically, the AAV genome of a naturally derived serotype or e or clade of AAV
comprises at least one inverted terminal repeat sequence (ITR). Vectors ofthe ion
typically comprise two ITRs, preferably one at each end of the genome. An ITR
sequence acts in cis to provide a fiinctional origin of replication, and allows for
integration and excision of the vector from the genome of a cell. Preferred ITR
sequences are those of AAV2 and variants thereof. The AAV genome typically
comprises packaging genes, such as rep and/or cap genes which encode packaging
ons for an AAV viral particle. The rep gene encodes one or more of the proteins
Rep78, Rep68, Rep52 and Rep40 or variants thereof. The cap gene encodes one or more
capsid ns such as VPl, VP2 and VP3 or ts thereof. These proteins make up
the capsid of an AAV viral particle. Capsid variants are discussed below.
Preferably the AAV genome will be derivatised for the e of stration to
patients. Such tisation is standard in the art and the present invention
encompasses the use of any known derivative of an AAV , and tives
which could be generated by applying ques known in the art. Derivatisation of
the AAV genome and of the AAV capsid are reviewed in, for example, Choi et al and
Wu et al, nced above.
Derivatives of an AAV genome include any truncated or d forms of an AAV
genome which allow for sion of a Rep-l transgene from a vector of the invention
in viva. Typically, it is possible to truncate the AAV genome significantly to e
minimal viral sequence yet retain the above function. This is preferred for safety reasons
to reduce the risk of ination of the vector with wild-type virus, and also to avoid
triggering a ar immune response by the presence ofviral gene proteins in the target
cell.
Typically, a derivative will include at least one inverted terminal repeat sequence (ITR),
preferably more than one ITR, such as two ITRs or more. One or more of the ITRs may
be derived from AAV genomes having different serotypes, or may be a chimeric or
mutant ITR. A preferred mutant ITR is one having a deletion of a trs (terminal
resolution site). This deletion allows for continued replication ofthe genome to generate
a single-stranded genome which ns both coding and complementary sequences
i.e, a self-complementary AAV genome. This allows for bypass ofDNA replication in
the target cell, and so enables accelerated transgene expression.
The one or more ITRs will preferably flank the expression construct cassette containing
the promoter and transgene of the invention. The inclusion of one or more ITRs is
preferred to aid packaging of the vector ofthe invention into viral particles. In preferred
embodiments, ITR elements will be the only sequences retained from the native AAV
genome in the derivative. Thus, a derivative will preferably not include the rep and/or
cap genes of the native genome and any other sequences of the native genome. This is
preferred for the reasons described above, and also to reduce the possibility of
integration of the vector into the host cell genome. Additionally, reducing the size of
the AAV genome allows for increased flexibility in incorporating other sequence
ts (such as regulatory elements) within the vector in on to the transgene.
With reference to the AAV2 genome, the following portions could therefore be
removed in a derivative of the invention: One inverted terminal repeat (ITR) sequence,
the replication (rep) and capsid (cap) genes. However, in some embodiments, including
in vitro embodiments, derivatives may additionally include one or more rep and/or cap
genes or other viral sequences of an AAV genome.
A derivative may be a chimeric, shuffled or capsid-modified derivative of one or more
naturally occurring AAV viruses. The invention encompasses the provision of capsid
protein ces from ent serotypes, clades, clones, or isolates of AAV within
the same vector. The invention encompasses the packaging of the genome of one
serotype into the capsid of another serotype i.e. pseudotyping.
Chimeric, shuffled or capsid-modified derivatives will be typically selected to provide
one or more desired fiinctionalities for the viral vector. Thus, these derivatives may
display increased ncy of gene delivery, decreased immunogenicity (humoral or
cellular), an d tropism range and/or improved targeting of a ular cell type
compared to an AAV viral vector sing a naturally ing AAV genome, such
as that of AAV2. Increased efficiency of gene delivery may be effected by improved
receptor or co-receptor binding at the cell surface, improved internalisation, improved
trafficking within the cell and into the nucleus, improved uncoating of the viral particle
and improved sion of a single-stranded genome to -stranded form.
Increased efficiency may also relate to an altered tropism range or targeting of a specific
cell population, such that the vector dose is not diluted by administration to tissues
where it is not needed.
ic capsid proteins include those generated by recombination between two or
more capsid coding sequences of naturally occurring AAV serotypes. This may be
performed for example by a marker rescue ch in which non-infectious capsid
sequences of one serotype are cotransfected with capsid sequences of a different
serotype, and directed selection is used to select for capsid sequences having d
properties. The capsid sequences of the different serotypes can be altered by
homologous recombination within the cell to produce novel chimeric capsid proteins.
Chimeric capsid proteins also include those generated by engineering of capsid n
sequences to transfer specific capsid n domains, surface loops or specific amino
acid residues between two or more capsid proteins, for example between two or more
capsid proteins of different serotypes,
Shuffled or chimeric capsid proteins may also be ted by DNA shuffling or by
error-prone PCR. Hybrid AAV capsid genes can be created by randomly fragmenting
the sequences of related AAV genes e.g. those encoding capsid ns of multiple
different serotypes and then subsequently reassembling the fragments in a riming
polymerase reaction, which may also cause crossovers in regions of ce
homology. A library of hybrid AAV genes created in this way by shuffling the capsid
genes of several serotypes can be screened to identify viral clones having a desired
functionality. Similarly, error prone PCR may be used to ly mutate AAV capsid
genes to create a diverse library of variants which may then be selected for a desired
property.
The sequences of the capsid genes may also be genetically modified to introduce
specific deletions, substitutions or insertions with t to the native wild-type
sequence. In particular, capsid genes may be modified by the insertion of a sequence of
an unrelated protein or peptide within an open reading frame of a capsid coding
sequence, or at the N— and/or C-terminus of a capsid coding sequence.
The unrelated protein or e may advantageously be one which acts as a ligand for
a particular cell type, thereby conferring improved binding to a target cell or improving
the city of targeting of the vector to a particular cell population.
The unrelated protein may also be one which assists purification of the viral particle as
part of the production process i.e. an epitope or affinity tag. The site of insertion will
typically be ed so as not to interfere with other fiinctions of the viral particle e. g.
internalisation, trafficking of the viral particle. The skilled person can identify suitable
sites for insertion based on their common l knowledge. Particular sites are
disclosed in Choi et a1, referenced above.
The invention additionally encompasses the provision of sequences of an AAV genome
in a different order and configuration to that of a native AAV genome. The invention
also encompasses the replacement of one or more AAV sequences or genes with
ces from another virus or with chimeric genes composed ences from more
than one virus. Such chimeric genes may be composed of ces from two or more
related viral proteins of different viral species.
The vector of the invention takes the form of a viral vector sing the promoters
and expression constructs of the invention.
The invention also provides an AAV viral particle comprising a vector ofthe invention.
The AAV les of the invention include transcapsidated forms wherein an AAV
genome or derivative having an ITR of one serotype is packaged in the capsid of a
different serotype. The AAV particles of the invention also include mosaic forms
wherein a mixture of unmodified capsid proteins from two or more different serotypes
makes up the viral envelope. The AAV particle also es ally modified
forms bearing ligands adsorbed to the capsid surface. For example, such ligands may
include antibodies for targeting a particular cell surface receptor.
The invention additionally provides a host cell comprising a vector or AAV viral
particle of the invention.
Vectors of the invention may be prepared by standard means known in the art for
provision of vectors for gene therapy. Thus, well established public domain
transfection, packaging and purification methods can be used to prepare a suitable
vector preparation.
As sed above, a vector of the invention may comprise the full genome of a
naturally occurring AAV virus in addition to a promoter of the invention or a variant
thereof. However, commonly a derivatised genome will be used, for instance a
derivative which has at least one inverted terminal repeat sequence (ITR), but which
may lack any AAV genes such as rep or cap.
In such embodiments, in order to provide for assembly of the derivatised genome into
an AAV Viral particle, additional genetic constructs providing AAV and/or helper virus
ons will be provided in a host cell in combination with the derivatised genome.
These additional constructs will typically contain genes encoding structural AAV
capsid proteins i.e. cap, VPl, VP2, VP3, and genes encoding other functions required
for the AAV life cycle, such as rep. The selection of structural capsid proteins provided
on the additional construct will ine the serotype of the packaged viral vector.
A particularly preferred packaged viral vector for use in the invention ses a
derivatised genome of AAV2 in combination with AAVS or AAV8 capsid proteins.
As ned above, AAV viruses are replication incompetent and so helper virus
functions, preferably adenovirus helper functions will typically also be ed on one
or more additional ucts to allow for AAV replication.
All of the above additional constructs may be provided as plasmids or other al
elements in the host cell, or alternatively one or more constructs may be integrated into
the genome of the host cell.
Pharmaceutical Compositions, Dosages and Treatments
2016/050419
The vector ofthe ion can be formulated into pharmaceutical compositions. These
compositions may comprise, in addition to the vector, a pharmaceutically acceptable
excipient, carrier, buffer, stabiliser or other als well known to those skilled in the
art. Such materials should be non-toxic and should not interfere with the efficacy of
the active ingredient. The precise nature of the carrier or other material may be
ined by the skilled person according to the route ofadministration, i.e. here direct
retinal, subretinal or intravitreal injection.
The pharmaceutical composition is typically in liquid form. Liquid pharmaceutical
compositions generally e a liquid carrier such as water, petroleum, animal or
vegetable oils, mineral oil or synthetic oil. Physiological saline solution, magnesium
chloride, dextrose or other saccharide solution or s such as ethylene glycol,
propylene glycol or polyethylene glycol may be included. In some cases, a surfactant,
such as pluronic acid (PF68) 0.001% may be used.
For injection at the site of affliction, the active ingredient will be in the form of an
aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
Those of relevant skill in the art are well able to prepare suitable ons using, for
example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection,
Lactated Ringer's Injection, Hartmann's solution. vatives, stabilisers, buffers,
antioxidants and/or other ves may be included, as required.
For delayed e, the vector may be included in a pharmaceutical composition which
is formulated for slow release, such as in microcapsules formed from biocompatible
polymers or in mal carrier systems according to methods known in the art.
The vectors and/or pharmaceutical compositions of the invention can be packaged into
a kit.
In general, direct retinal, subretinal or intravitreal delivery of vectors of the invention,
lly by injection, is preferred. Delivery to the retinal, subretinal space or
intravitreal space is thus preferred. Vectors may also be introduced into rod
photoreceptors in vitro followed by cell transplantation into the retina
The vectors and/or pharmaceutical compositions of the invention can also be used in
combination with any other y for the treatment or prevention of vision disorders.
For example, they may be used in combination with known treatments that employ
VEGF antagonists, eg anti-VEGF dies such as Bevacizumab or Ranibizumab or
soluble receptor antagonists such as Aflibercept, for the treatment of AMD or other eye
disorders as discussed herein.
Dosages and dosage s can be determined within the normal skill of the medical
practitioner responsible for administration of the composition. The dose of a vector of
the invention may be determined according to various ters, especially according
to the age, weight and condition of the patient to be treated, the route of administration,
and the required regimen. Again, a physician will be able to determine the required
route of administration and dosage for any particular patient.
A typical single dose is between 1010 and 1012 genome particles, depending on the
amount of retinal tissue that requires transduction. A genome le is d herein
as an AAV capsid that ns a single stranded DNA molecule that can be quantified
with a sequence specific method (such as real-time PCR). That dose may be provided
as a single close, but may be repeated for the fellow eye or in cases where vector may
not have ed the correct region of retina for whatever reason (such as surgical
complication). The treatment is preferably a single permanent treatment for each eye,
but repeat injections, for example in future years and/or with different AAV serotypes
may be considered.
Treatments
2016/050419
Vectors of the invention may be used to treat any ocular condition in which there is
dysfunction, ration or absence of cones but at least some healthy rods remain.
Cone function may be wholly or partially missing, e.g. at least 10%, at least 25%, at
least, at least 50%, at least 75%, at least 80%, at least 90% or more missing. y
rods are rods that are capable of performing normal or partial, e.g. at least 10%, at least
%, at least, at least 50%, at least 75% or at least 90% of normal rod function in terms
of perception of light at scotopic levels.
Conditions that can be treated using vectors of the ion thus include macular
degeneration, achromatopsia and Leber congenital amaurosis. The macular
degeneration may be age-related macular degeneration (AMD), for example wet or
neovascular AMD or geographic atrophy, an inherited macular degeneration condition
or an ted cone dystrophy. In some embodiments, the invention will result in the
creation of a ‘pseudo-fovea’, a small patch of cone-like rods that improves vision in
conditions in which foveal cones have been lost or are dysfunctional.
In l, patients to be treated with vectors of the invention will be human patients.
They may be male or female and of any age.
The ing Examples illustrate the invention.
EXAMPLES
Example 1 - Methods for ArchT experiments.
Animals
Wild-type mice (C57BL/6J) were purchased from Harlan Laboratories (Blackthorn,
UK). CNGA3-/— and PDE6C—/— mice were bred in house. All mice were maintained
under cyclic light (12 h light-dark) conditions; cage illumination was 7 foot-candles
during the light cycle. All experiments were approved by the local Institutional Animal
Care and Use Committees (UCL, London, UK) and conformed to the guidelines on the
care and use of animals adopted by the Society for Neuroscience and the Association
for Research in Vision and Ophthalmology (Rockville, MD).
Plasmid uctions, viralproduction and injection procedure
The transgene construct (ArchT-EGFP) was kindly provided by Prof Ed Boyden (MIT,
USA) and ns the cDNA sequence of the ArchT gene fused to the fluorescent
n EGFP. The ds were packaged into AAV8 to generate recombinant AAV
viral s, ho.ArchT-EGFP. Recombinant AAV8 vector was produced
through a triple transient transfection method as described previously. The plasmid
construct, AAV serotype-specifrc ing plasmid and helper plasmid were mixed
with hylenimine (Polysciences Inc.) to form transfection complexes, which were
then added to 293T cells and left for 72h. The cells were harvested, concentrated and
lysed to release the vector. AAV8 was purified using AVB Sepharose columns (GE
Healthcare). Both were washed in 1X PBS and concentrated to a volume of 100—150
uL. Viral particle titres were determined by comparative dot-blot DNA prepared from
purified viral stocks and defined plasmid controls. Purified vector concentrations used
for all experiments were 5 X 1012 viral particles/ml. Subretinal injections were
performed as described previously by our group and consisted of double injections of
2ul each.
Immunohistochemistry
Animals were euthanized, the eyeballs enucleated and cornea, lens and iris removed.
For retinal sections, the eyecups were fixed in 4% paraformaldehyde (PFA) for 1 hour
at room temperature, before ing in optimal cutting temperature (OCT) medium.
30pm cryosections were cut in sagittal orientation, rinsed with PBS and blocked in 10%
normal goat serum (NGS), 3% bovine serum albumin (BSA) and 0.1% Triton-X100.
The respective samples were incubated with primary antibodies in block on at 4°C
ght using rabbit anti-cone arrestin (diluted 1:500). Following PBS washes, the
respective combination of secondary antibodies (all d 1:500, life technologies)
including goat anti rabbit Alexa Fluor 546 (#A1 103 5), goat anti mouse Alexa Fluor 633
(#A21052) and avidin, Alexa Fluor 633 conjugate (#S2l375) were used to label
the samples before these were counterstained with DAPI and d with DAKO
fluorescent mounting media (DAKO, S3023, Denmark). Images were acquired by
confocal microscopy (Leica DM5500Q).
Single photoreceptor suction recordings
s were dark d for 12h prior to the start of experiments. Mice were
administered an overdose ofketamine-dormitor anaesthetic mix via the intra- peritoneal
cavity, to induce terminal surgical-plane anaesthesia. Mice were then sacrificed by
cervical dislocation and enucleated. Eyes were dissected under dim, far-red
illumination. ed retinas were imbedded in 1% low melting agarose solution and
then cut using a vibrotome (leica) into 23 Oum thick en face slices. Slices were mounted
in a recording chamber and perfused with carbogen (95% 02 5% C02) saturated Ames
medium containing 100nm 9-cis retinal (Sigma) and 0.2% BSA (Sigma). The
temperature of the perfiision on was maintained at 37°C using an in-line heating
element under feedback control (Scientifica). Very low resistance (1—2MQ ) patch
pipettes were made from fllamented boroscilicate glass capillaries (Harvard Apparatus
Ltd) using a Narishige PC-10 al puller. Pipettes were filled with external on,
mounted onto the headstage and a small pressure applied across the tip (~30mbar).
Using infrared illumination and a microscope to aid visualisation the pipette was placed
onto the surface ofthe retina, and then lowered ~50um into the slice, until photoreceptor
segments appeared intact and neatly arranged. Slight negative pressure was applied
across the pipette tip as it was advanced slowly through the retinal , using a
100ms, 10mV test pulse to monitor resistance across the pipette tip. When ance
increased to ~20-30MQ light evoked responses were tested. Light stimuli from an LED
light-source (peak wavelength 530nm) d to a liquid light guide, were delivered
h the microscope objective (Olympus). Neutral density filters were used to
precisely control the intensity of the light us. Light stimuli consisted of square
wave pulses programmed using P-Clamp software ular Devices), and delivered
via a DAC board (Axon Instruments) in conjunction with an LED driver (Thorlabs).
Electrophysiological ings were carried out using a Multiclamp 700B amplifier
(Molecular Devices). Data was digitized at 20kHz.
MEA ings
Animals were dark adapted for 12h prior to the start of experiments. Mice were
administered an overdose ofketamine-dormitor anaesthetic mix via the intra— peritoneal
cavity, to induce terminal surgical-plane anaesthesia. Mice were then ced by
cervical dislocation and enucleated. Eyes were dissected in en (95% Oxygen, 5%
Carbon Dioxide) saturated Ames medium (Sigma), under dim red light. The cornea and
lens were removed, with care taken to remove as much vitreous from the surface ofthe
retina as possible. The RPE was separated from the retina and a flat petal 1-3 mm across
was cut away from the retinal ’cup’. This retinal petal was placed ganglion-cell side
down on the surface of the lectrode array, and a circular harm constructed from
unreactive platinum wire (Sigma) and nylon was used to keep the petal in position.
Throughout recordings, the tissue was perfused with carbogen saturated Ames medium
(Sigma), maintained at a temperature of 36.5 degrees Celsius. For recordings that
included scotopic or mesopic ions, the perfusion medium was made up to include
9-cis retinal (Sigma), at a concentration of lOOuM, in 0.2% BSA (Sigma). A perforated
60-electrode recording array, consisting of tungsten electrodes spaced 100 mm apart
(Multi Channel Systems) was used to record ganglion cell extracellular ials.
Voltage changes were amplified and digitized at 50kHz by an MC Card system, using
MC Rack software (MultiChannel Systems).
Electrophysiological data analysis
Electrophysiological data was analysed using custom-written macros in IgorPro 6.
ic currents and potentials were detected using an amplitude threshold algorithm
where the threshold for event detection was set at 2 times the standard deviation of the
baseline noise ally about lOpA). Detected currents and potentials were d
manually through careful inspection of all electrophysiological data.
Fear conditioning
Mice were trained and tested using a commercially available fear conditioning system
(Med Associates). To ensure blind conditions, the experimenter performing the training
and testing was always blind to the strain of mouse and treatment conditions. Briefly,
the setup consisted of a conditioning chamber (20x30 cm) with a stainless steel grid
floor placed inside a sound—attenuating cubicle. Mouse behaviour was monitored
constantly during training and testing by means of a in infrared l video
camera (30 frames/s acquisition rate) and ed illumination. Video Freeze software
(Med Associates) was used to control delivery of the light stimulus and shock. The light
stimulus consisted of a single LED (530 nm, Thorlabs) 5 Hz 50ms full-brightness
flicker generated via an Arduino interface (Arduino Software) positioned on a side
panel of the ioning chamber. To ensure that the context in which training and
testing took place were different, floor and curved wall panels were inserted into the
chamber for the testing session. A background white light was used to reduce chances
ofrod activation and pupils were dilated with Tropicamide drops to increase the amount
of light reaching the mouse retina.
Mice were placed inside the r and underwent one conditioning session,
consisting of 6 pairings of a 5 5, light stimulus that co-terminated with a 2 s, 0.65 mA
foot shock. Inter-trial interval was pseudo-randomized (average interval 90 3).
Following the training session mice were returned to the home cage, 24 hours after
training, mice were tested for ly cued memory recall. Mice were placed in the test
chamber and monitored for a total of 360 s. The conditioning light us was
presented continuously for the last 120 s of the test n. All data was acquired and
scored automatically by VideoFreeze software (Med ates). Briefly, the re
is calibrated before placing the animal in the chamber. The software then measures the
pixel changes that take place between every video frame. The motion threshold was set
to be as low as possible (20 motion index units), and the continuous freezing count was
set to the frame rate to ensure the most sensitive read—out of motion. To assess light
cued memory recall the percentage time of freezing behaviour was averaged for the two
s immediately prior to and following the light stimulus onset. Statistical
significance was assessed with a one-way ANOVA Results are presented as mean ::
S.E.M.
Optomotry
Visual acuities were measured by observing the optomotor responses ofmice to rotating
sinusoidal gratings (OptoMotry, Cerebral Mechanics). The protocol used yields
independent measures of the acuities of right and left eyes based on the unequal
sensitivities of the two eyes to pattern rotation as only motion in the temporal-to-nasal
direction evokes the tracking se. As a result, the right and the left eyes are most
sensitive to counter-clockwise (CCW) and ise (CW) rotations, respectively.
Stimuli of ent temporal frequency were used to determine the threshold at which
a response was present. A double-blind two-altemative forced choice procedure was
employed, in which the observer was ’ to the direction of pattern rotation, to
whether it was an ArchT-treated or untreated CNGA3-/- 0r /— mouse or age-
matched ype control animal (C57BL6). Visual acuity was measured in both eyes
ofthe tested animal and averaged or separately analyzed for each eye after 4 trials were
conducted on 4 separate days. The measurement was carried out on injected mice 3—10
weeks after treatment together with age-matched isogenic controls.
Example 2 - ArchT expression in rod photoreceptors s the ability to d
with rapid non-bleaching responses
Rod—mediated vision is optimized for low light levels, including single photon
ion. However, rods cannot match the rapid onset and recovery of cone responses
to light (Fu et al., 2007, Pugh et al., 1999). This functional difference, useful to ensure
reliable vision in different environments, becomes debilitating when cone-mediated
vision is lost in conditions such as in age-related macular degeneration, when the
densely packed cones in the fovea degenerate (de Jong 2006). It was investigated
whether if rods could respond and recover more quickly to stimuli, this would help
alleviate the functional impairment caused by the loss of cones.
A fast light-driven proton pump (ArchT) (Han et a1., 2011) was expressed in rod
photoreceptors. AAV8 particles carrying ArchT—EGFP under control of the Rhodopsin
promoter (Rho) were injected subretinally in adult mice. Expression of chT-
EGFP was limited to the membrane of rod photoreceptors (Figuresla-b). Synaptic
terminals of rods expressing Rho-ArchT-EGFP and cones could be easily distinguished
following immunohistochemistry e 1c). tative PCR on a sorted population
of cones ed that Rho-ArchT-EGFP expression was specific to the rod
population and no evident sign of toxicity was observed up to 6 months ing
AAV8 injection. Expression of ArchT allowed extremely rapid light responses, while
the intrinsic rod response was preserved and was comparable to that observed in non-
transduced rod photoreceptors (Figure 1d). evoked currents recorded from
ArchT-expressing rods trated considerably faster kinetics than the intrinsic rod
currents in all mouse models tested (Figure 2a—b). These kinetics allowed light evoked
currents to be modulated up to 80 Hz, far above the limits of both rods, which faltered
at ~20 Hz (Figure 2a—c), and of cones (Fu et al., 2007).
Surprisingly, ArchT expression did not alter the properties of rod photoreceptors while
conferring the y to respond with rapid non—bleaching responses (Figure 2e).
Example 3 - ArchT—expressing rods drive sustained RGC spiking at high light
intensities and at frequencies ching those of cone photoreceptors
It was next investigated whether the circuitry driven by rods would be able to follow
faster-than-normal rod-driven Vision. Rod and cone pathways present some similarities
and some striking differences and it is therefore not clear whether the rod circuitry can
ly sustain fast ‘cone-like’ transmission (Wassle et al., 2004). Rods have been
shown to contact OFF ‘cone’ bipolar cells directly (Soucy et al., 1998 and Hack et al.,
1999) and paired-pulse stimulation suggests that this alternative pathway may be as fast
as the cone—to-OFF-bipolar one (Li et al., 2010). However, it is not clear how sustained
this response can be and whether rod (ON) bipolar cells can also sustain fast
transmission. Furthermore, rod synaptic terminals have different size and ultra-
structural zation ed to cones and rod bipolar cells do not contact Retinal
Ganglion Cells (RGCs) directly but only through a pathway involving AII amacrine
cells (Wassle et al., 2004). To investigate the maximal speed that the rod pathway can
achieve, multi-electrode ings from RGCs in mouse models g cone function
were performed, to isolate rod-mediated RGC output. Rod-driven ses in RGCs
in non-transduced retinas were bleached at high light levels and could not follow
stimulation ncies higher than ~20 Hz (Figure 2f).
On the contrary, ArchT-expressing rods drove sustained RGC spiking at high light
intensities and at frequencies approaching those of cone photoreceptors (Figure 2f).
Example 4 - expression of chT-EGFP extended the sensitivity of mice
lacking cone-mediated vision to bright light stimuli
For this -than-normal rod vision to be , it was reasoned that mice should be
able to use ArchT-mediated currents to reliably respond to bright and fast stimuli.
CNGA3'/' and PDE6C'/' mice lacking cone-mediated vision (Biel et al., 1999 and
Change et al., 2009) failed to learn a fear conditioning paradigm where bright light
stimuli were paired and co-terminated with a mild foot shock (Figure 3a). However,
expression of Rho-ArchT-EGFP ed the sensitivity of these mice to bright light
stimuli, allowing learning of the association between visual stimulus and shock (Figure
3a). Finally, it was tested whether ArchT expression red fast vision to CNGA3'/'
and PDE6C'/' mice. Assessment of the speed of vision by means of Optomotor testing
(Umino et all, 2008) showed that ArchT-expressing mice were able to follow stimuli
faster than mice that did not o subretinal viral ions and mice that received
a GFP-only vector (Figure 3b). The maximal frequency of stimuli that ArchT-
expressing mice could follow was similar to that of cone photoreceptors (Figure 3b).
Together, these results show that rods can be driven faster than by their intrinsic photo-
transduction cascade and that rod-driven circuits can sustain a faster signalling.
Importantly, synaptic release from rods does not require large voltage fluctuations, but
small currents can instead cause sufficient voltage variations to significantly alter their
synaptic transmission (Cangiano et al., 2012). This extends the use of the Invention to
light levels several-fold lower than the average light levels required for optogenetic
manipulation of activity in most other s (Han et al., 2011).
Example 5 - s for RPAP ments
Animals
C57BL6 (Harlan, UK), /- (J.R. Heckenlively, University of Michigan), Pde6c-
/- (J.R. lively, University of Michigan, MI) (Chang et al., 2009), and GnatI-/-
(J. Lem, Tufts University School of Medicine, MA) (Calvert et all, 2000) mice were
maintained in the animal facility at University College London. Adult male and female
animals were 6-12 weeks old at the time of viral injection and were used for
experiments at least 2 weeks after the injection to allow for a ient expression of
R9AP. All the mice used were between ages of 2 to 6 months and were age matched
between groups of a given experiment. All experiments have been conducted in
accordance with the Policies on the Use of Animals and Humans in Neuroscience
ch and with the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. Animals were kept on a standard 12/12 hour light-dark cycle
Plasmid constructions andproduction ofrecombinant AA V8
The murine R9ap cDNA was PCR amplified from murine retinal cDNA using primers
which have been designed to encompass the whole of the coding region. The R9ap
cDNA was cloned between the promoter (CMV promoter or bovine sin
promoter) and the SV40 polyadenylation site. These plasmids were used to generate
two pseudotyped AAV2/8 viral vectors, 8.CMV.mR9ap and
rAAV2/8.Rho.mR9ap, as described below.
Recombinant AAV2/8 vector was produced through a triple transient transfection
method as described previously (Gao et al., 2002). The plasmid construct, AAV
serotype-specific packaging plasmid and helper plasmid were mixed with
polyethylenimine to form transfection xes which was then added to 293T cells
and left for 72 h. The cells were harvested, concentrated and lysed to release the vector.
The AAV2/8 was purified by affinity chromatography and concentrated using
ultrafiltration columns rius Stedim Biotech, Goettingen, Germany), washed in
PBS and concentrated to a volume of 100—150 ul. Viral particle titres were determined
by dot-blot or by ime PCR. d vector concentrations used were 1-2 X 1012
viral particles/ml.
Electroretinogram (ERG)
ERGs were recorded from both eyes after mice were dark adapted overnight using a
commercially available system (Espion E2, Diagnosys LLC, , MA). The animals
were anesthetized with an eritoneal injection of a 0.007 ml/g mixture of
medetomidine hydrochloride (1 mg/ml), ketamine (100 mg/ml), and water at a ratio of
53:42 before recording. Pupils were fully dilated using 2.5% phenylephrine and 1.0%
tropicamide. Midline subdermal ground and mouth reference electrodes were first
placed, followed by positive silver electrodes that were allowed to y touch the
center of the corneas under dim red illumination. A drop of Viscotears 0.2% liquid gel
(Dr. Robert Winzer /OPD Laboratories, Watford, UK) was placed on top of the
positive electrodes to keep the corneas moistened during recordings and the mouse was
allowed to further dark-adapt for 5 minutes. Bandpass filter cutoff frequencies were
0.312 Hz and 1000 Hz. Recovery speed of photoresponse was measured using paired
flash paradigm where pairs of flashes with identical saturating intensity (1.8
log.cd.s/m2) ted by various stimulus als (ISI, 05 12 4 816,32,64) 7 7 7 7
sec) were ted. In this paradigm, the 1St flash would completely suppress the
electric responses of rod mechanisms which allow observation of the speed of
functional recovery of the rod fiinction by presenting 2‘“d flash with different ISI.
Sufficient amount of time (150 sec) were provided between pairs of flashes to allow
full recovery of the 1St flash. Then the recovery of a-wave amplitude observed should
reflect the speed of deactivation of the rods in animals devoid of cone function since
the flash should only bleach a fraction ) of the rhodopsin (Lyubarsky et al., 2004
and Weymouth, A.E. & Vingrys 2008). ic 6 Hz flicker intensity series were
performed as usly reported with a few modifications ger et al., 2001). 17
steps of flash intensities were used ranging from -6 to 2 log.cd.s/m2 each separated by
0.5 log unit. For each step, after 10 seconds of adaptation, 600 msec sweeps were
averaged 20 times using the same flash condition. Series of dark-adapted responses
were also obtained using longer flashes with durations of 20, 100, and 200 msec all at
83.3 cd/mz. Standard single flash scotopic recordings were obtained from dark-adapted
animals at the following increasing light intensities: -6, -5, -4, -3, -2, -1, 0, 1.0, 1.5, and
1.9 log.cd.s/m2. Photopic flash recordings were performed following 5 min light
adaptation intervals on a background light intensity of 20 cd/mz, which was also used
as the background light for the duration of the ings. Photopic light intensities
used were -2, -1, 0, 1, 1.5, and 1.9 log.cd.s/m2.
Histologg/
SiX weeks after unilateral inal injection of rAAV2/8.Rho.mR9ap, both eyes from
a Cnga3-/- mouse were y removed and snap frozen in liquid nitrogen. After
cryoembedding the eye in OCT (RA Lamb, Eastborne, UK), the eyes were cut as
transverse sections 15 um thick and were air-dried for 15 - 30 min. For
immunohistochemistry, sections were pre-blocked in PBS containing normal donkey
serum (2%), bovine serum albumin (2 %) 1 hr before being incubated with G89
antibody (1:500, Santa Cruz Biotechnology, SantaCruz, CA) for 2 hours at room
temperature. After rinsing 2 x 15 min with PBS, sections were incubated with the
appropriate Alexa 546-tagged secondary antibody (Invitrogen, Carlsbad, CA) for 2 hrs
at room temperature (RT), rinsed and counter-stained with Hoechst 33342 -
Aldrich, Gillingham, UK). Retinal sections were viewed on a confocal microscope
(Leica TCS SP2, Leica Microsystems; Wetzlar, Germany).
Western blotting
The eyes from a /- mouse 4 weeks after unilateral subretinal injection of
rAAV2/8.Rho.mR9ap were ted. After separating the neural retina from the
RPE/choroid/sclera complex, tissues were homogenized in RIPA buffer and left on ice
for 20 s. The samples were centrifuged at 16,000 g for 30 minutes at 4 oC and
stored in -20°C until use. Western blotting was carried out using known protocols.
Optomotor responses and contrast sensitivityfunction
Contrast sensitivities and visual acuities of treated and untreated eyes were measured
by observing the optomotor responses of mice to ng sinusoidal gratings
(OptoMotryTM, Cerebral Mechanics, Lethbridge, AB Canada). The protocol used yields
independent measures of the acuities of the right and the left eyes based on unequal
ivities of the two eyes to pattern rotation: the right and the left eyes are driven
primarily by counter—clockwise and clockwise rotations, respectively (Douglas et al.,
2005). A mouse was placed on a small island isolated from the floor in a closed space
surrounded by 4 rs with rotating sinusoidal grating with a mean illuminance of
62 cd/mz. A double-blind two-altemative forced choice procedure was employed, in
which the observer was ‘blind’ to the direction of pattern rotation, to whether it was a
treated or untreated Cnga3-/- mouse or age-matched wild—type control animal
(C57BL6). The contrast sensitivity measured at 0.128, 0.256, 0.383, 0.511
cycles/degree presented at 6 Hz was defined as 100 divided by the lowest percent
contrast yielding a threshold response. Both eyes of each mouse were tested four times
on independent days. The data was projected on to a Campbell-Robson st
Sensitivity Chart with sinusoidal gratings representing relative spatial frequencies,
Rhodopsm measurement
After fully dark-adapting the mice overnight, the mice were anaesthetized and the
pupils were fully d to assess the speed of visual pigment bleaching. Then the mice
were placed in a light box with a light source (7.0 mW) directly illuminating the eye
for 5 minutes before the eyes were collected. In another experiment, mice were d
to an identical condition as that for measuring contrast sensitivity for various durations
(0, 30 60, 120 s). The mouse eyes were removed at each time point and placed
in 250 pl of phosphate buffered saline and snap frozen in liquid nitrogen in a light tight
tube and kept at —20 °C until use. Some eyes were collected in the dark under red
nation after ght dark-adaptation of the mice. Spectrophotometric
measurement of rhodopsin were performed as previously reported with minor
modifications (Douglas et al., 1995). In brief, the samples were thawed at room
temperature and homogenized. This and all uent operations were med
under dim red nation that bleaches the visual pigments minimally. Fifty
iters of n-dodecyl B-D-maltoside (200 mM; Sigma-Aldrich, St. Louis, MO) was
added to every sample and the resulting mixture rotated for 2 h at room temperature,
followed by 10 min centrifugation 0 g) at 4°C. The supernatant was removed and
placed in a quartz cuvette in a Shimadzu UV-2101PC spectrophotometer (Shimadzu,
Kyoto, . After an initial scan of the unbleached extract from 300 nm to 700 nm,
the sample was exposed to monochromatic light (502 nm) for 3 minutes, shown to be
enough to completely bleach rhodopsin (Longbottom et al., 2009), and rescanned. All
absorption spectra were zeroed at 700 nm. Difference spectra were constructed using
the pre- and post-bleach curves and the maximum optical densities at N 500 nm
determined, representing the amount of the extracted visual pigment.
Example 6 - R9AP over-expression in rods and increased speed of eceptor
deactivation
RG89, G85, and R9AP are obligate members of the regulatory GTPase complex. To
study the effect of AAV-mediated R9AP over—expression on the GTPase complex in
the rods, the level and distribution of RG89 was examined following subretinal
injection of rAAV2/8.Rho.mR9ap in Cnga3-/- mice. These mice have normal rod
function but absent cone function and serve as a model of achromatopsia. Four weeks
later, treated retina showed sed immunoreactivity against RG89 throughout the
eceptor layer in the treated compared to the untreated retinas (Figure 4A).
Westernblot is further confirmed the increased RG89 n expression in the
treated retina (Figure 4B). These results indicated that the over—expression of R9AP
using AAV2/8 effectively increased the level of catalytic ent RG89 and the
GTPase complex.
Next the fiJnctional effect of AAV2/8-mediated R9AP over-expression on rod
phototransduction was studied by applying paired-flash ERG rsky and Pugh
1996). In this paradigm, a pair of identical flash intensity is delivered with a variable
inter-stimulus interval and the recovery of the second response relative to the first is
WO 35457
measured. In the rod photoreceptor pathway, the speed of the a-wave (originating from
photoreceptors) recovery is dependent on the speed of the deactivation, It was found
that the time nt (6) for 50% recovery of a—wave amplitude was d by ~60%
in the Cnga3-/— eyes injected with rAAV2/8.CMV.mR9ap (o = ~ 2.99 sec) ed
to the ted eyes (6 = ~ 7.38 sec; Figure 4C). rly, an increased speed of a-
wave recovery was observed using rhodopsin promoter (rAAV2/8.Rho.mR9ap, c5 = ~
2.74 sec, Figure 4C) in the same mouse line (Cnga3-/-) or the same virus
(rAAV2/8.CMV.mR9ap) in another efective mouse line -/—; Figure 8).
These observations indicated that the subretinal injection of rRAAV2/8.CMV.mR9ap
or rAAV2/8.Rho.mR9ap can significantly increase the deactivation speed of the rod
phototransduction through sing the level of RGS9 and GTPase complex.
Example 7 - “Photopic shift” of rod function by over-expression of R9AP
To investigate if an increased deactivation speed achieved by overexpression of R9AP
and GTPase complex in the rods could alter the operating range of the photoreceptor
function, dark-adapted 6 Hz flicker ERGs were recorded using incremental flash
intensities. The eyes treated with rAAV2/8.CMV.mR9ap or rAAV2/8.Rho.mR9ap
showed increased responses to brighter flashes compared to the untreated eyes. This
resulted in an elevation the upper threshold ofthe response by up to ~2 log units (Figure
5A), with little effect on the maximal photoresponse (151 i 17 uV in the treated vs 162
:: 29 uV in the untreated eyes; average i standard error of the mean). As expected, this
“photopic shift” in the operating range of the rods was accompanied by a reciprocal
elevation the lower threshold of the response by up to ~15 log units. Meanwhile, upper
threshold ofERG responses of wild-type eyes and GnatI-/- eyes, both with functional
cones, were elevated by ~40 log units compared to that of the untreated Cnga3-/— eyes.
Similar results were obtained when rAAV2/8.Rho.mR9ap was injected into Pde6c-/-
mice (Figure 9). As a consequence, the treatment allowed the rods to d to flashes
of longer durations (Figure 5B) and to flashes under a solating background
WO 35457
illumination e 5C). These include conditions where the untreated rods showed
virtually no response.
Taken together, these results ished that R9AP-over expression in rods results in
their desensitization and endows the cells to gain photopic filnction in exchange for
scotopic function. This therapeutic induction of “photopic shift” of the rod function
lasted at least for 5 months without overt evidence of retinal degeneration (Figure 10).
Meanwhile, the treatment of wildtype mice using the same viral vectors failed to show
a measurable change in l function (Figure 11).
Example 8 - Rod bipolar pathway accommodates the transmission of altered rod
function.
This work has established that an pression of R9AP in rods s in faster
photoreceptor deactivation cs and allows the neuron to respond to larger amount
of photons, Meanwhile, the rated deactivation should also result in a shorter
duration of the neurotransmitter release at the photoreceptor synaptic terminal.
Therefore, it was assessed whether the down-stream rod bipolar signaling is affected by
the treatment. First the speed and the extent of transmission of signals from the
photoreceptors to the r cells to a short single flash was studied by measuring the
implicit time and amplitudes of the a-wave (originating from the photoreceptors) and
b-wave (originating from the r cells) using ERG (Figure 6a). Overall, slightly
smaller but a nearly identical intensity-response curve was observed for the treated and
the untreated eyes for both a—wave and b-wave. The small difference observed may
reflect either the true consequence of rated photoreceptor deactivation or merely
the neural damage induced by the subretinal injection. The a-wave implicit time marks
the point at which the bipolar cell-driven b-wave becomes detectable. We also observed
a small delays in the a-wave and the b—wave implicit times, indicating a modest delay
exists in the transmission of neural signals from eceptors to bipolar cells.
Nevertheless, a relatively large variation of ERG responses between individuals
indicate a small delay or ion in rod se do not necessarily translate into
Visual dysfunction (Birch and Anderson 1992).
Therefore, these results indicated that, in principle, the r cells almost fiJlly
accommodate the alteration of photoreceptor on and, importantly, display an
appropriate dose-response onship.
Example 9 - R9ap over-expression results in improved Contrast Sensitivity
Function
Next, it was asked if the “photopic shift” of the rod function by R9AP over-expression
were consequently translated into improved Visual performance under light by
measuring optokinetic response to rotating sinusoidal gratings under the brightest
recording condition possible with a standard computer monitor (62 cd/mz) (Carvalho et
al., 2011). The unique advantage of this oral test is that Visual function of each
eye can be studied separately; the function of the right eye can be probed by responses
to counterclockwise (CCW) gratings and the left eye by clockwise (CW) stimuli
(Douglas et al., 2005). The spatial contrast sensitivity function (CSF) was studied with
a fixed temporal frequency of 6.0 Hz and found that Cnga3-/— mice had reduced CSF
ed to the wildtype mice e 7). CSF, a function of contrast sensitivity and
Visual acuity, displayed the estimate range of Visual perception (animals could
presumably perceive the gratings under the curve but not above, Figure 7A).
Intriguingly, an 80-fold (P = 0.005) and 54-fold (P = 0011) increase in the sensitivity
using gs of both 0.128 and 0.256 cycles/degree (c/d), respectively, was observed
when contrast sensitivity of the treated and the ted eyes were compared (Figure
7A left panel). No clear alteration of contrast sensitivity was observed for gratings of
0.383 (P = 0.056) and 0.511 (P = 0.111) c/d. Interestingly, the average sensitivity of
the treated eye in /— mice exceeded that of the wild-type controls with normal
cone function. However, when wild-type mice were treated with the same Viral
uct, CSFs were not different between the d and the untreated eyes (Figure
12).
Having established that R9AP overexpression results in gain of visual performance
when g maximally bright monitor settings, it was sought to determine ifthis gain-
of—vision is sustainable. This is of a valid concern considering that the ration of
visual pigment in rods is known to be considerably slower than that of the cones (Wang
and Kefalov 2011). First, it was assessed if the treatment results in tion in the
speed of visual pigment ing. It was found that an exposure of the treated and
untreated eyes to a bright light for 5 minutes did not yield any difference in the levels
of residual bleachable visual pigment (Figure 7B lower left panel). Second, the amount
of bleachable sin in the eye was studied after exposing the Cnga3-/- mice for a
variable amount of time to the same experimental condition carried out for CSF
measurement. The results showed that visual t level remained stable without
evidence of reduction throughout 2 hours’ exposure to the visual stimuli similarly for
the treated and the untreated eyes (Figure 7B lower right panel). These results indicated
that the gain of visual perception in the treated Cnga3-/— mice is supported by sufficient
supply of rhodopsin molecules and is sustainable.
REFERENCES
Curcio, C.A., et al. The Journal ofcomparative neurology 292, 497-523 (1990).
Dryj a, TB Americanjournal ofophthalmology 130, 547-563 .
Hess, R.F. & , K. The Journal ofphysiologfy 371, 365-3 85 (1986).
Nishiguchi, K.M., et al. Human mutation 25, 248-258 (2005).
Kohl, S., et al. Nature cs 19, 257-259 (1998).
Chang, B. et al. P.N.A.S 106, 19581-19586 (2009).
Thiadens, A.A., et al. Americanjournal ofhuman genetics 85, 240-247 (2009).
Burns, M.E. & Pugh, EN. Biophys J97, 153 8-1547 (2009).
Burns, M.E. & Pugh, EN. Physiology 25, 72-84 (2010).
Baseler, H.A., et al. Nature cience 5, 364-370 (2002).
Martemyanov, KA. & Arshavsky, V.Y. ProgMol Biol Transl 86, 205-227 (2009).
Krispel, C.M., et al. Neuron 51, 409-416 (2006).
Cowan, C.W., et al. P.N.A.S. 95, 5351—5356 (1998).
Zhang, X, Wensel, T.G. & Kraft, T.W. lhe Journal of neuroscience: the ofiicial
journal of the Societyfor Neuroscience 23, 297 (2003).
Nishiguchi, KM et al. Nature 427, 75-78 (2004).
Michaelides, M., et al. Ophthalmology 117, 120—127 6121 (2010).
Han, X. et al. Front Syst Neurosci. 5, 18 (2011).
Busskamp, V., et al. Science 329, 413-417 (2010).
Fu, Y., Yau, KW. Pflugers Arch. 454, 805-819 .
Pugh, EN. Jr et al. Curr Opin Neurobiol. 9, 410-418 (1999).
de Jong, P.V.T.M. NEngl JMed 355, 1474-1485 (2006).
Wassle, H. Nat Rev Neurosci. 5, 747-757 (2004).
Soucy, E. et al. Neuron 21, 481-493 (1998).
Hack, I. et al. P.N.A.S. 96, 14130-14135 (1999).
Li, W. et al. Nat Neurosci 13, 414-416 (2010).
Biel, M. et al. P.N.A.S. 96, 557 (1999).
Umino, Y. et al. JNeurosci 28, 189-198 (2008).
Cangiano, L. et al. ol. 590, 3841-3855 .
Berndt, A. et al. Science 344, 420-424 (2014).
Wietek, J. et al. Science 344, 2 (2014).
t, RB. et al. P.N.A.S 97, 13913-13918 (2000).
Gao, G.P. et al. S 99, 11854-11859 (2002).
Lyubarsky, AL, et al. Vision research 44, 3235-3251 (2004).
Weymouth, A.E. & Vingrys, A.J. Progress in retinal and eye research 27, 1-44 .
Seeliger, M.W., et al. Nature genetics 29, 70-74 (2001).
s, R.M., et al. Visual neuroscience 22, 677-684 (2005).
Douglas, R.Hl, et al. Journal of Comparative Physiology a-Sensory Neural and
Behavioral Physiology 177, 111-122 (1995).
Longbottom, R., et al. P.N.A.S. 106, 18728-18733 (2009).
Lyubarsky, A.L. & Pugh, E.N., Jr. The Journal ofneuroscience .' the oflicialjournal of
the yfor Neuroscience 16, 563-571 (1996).
Birch, D.G. & Anderson, J.L. Archives ofophthalmology 110, 1571-1576 (1992),
Carvalho, L.S., et al. Human molecular genetics 20, 3161-3175 (2011).
Wang, J.S. & Kefalov, VJ. Progress in retinal and eye research 30, 115-128 (2011).
, A. W., Ocular immune privilege, Eye, 23, 1885-1889 (2009).
Natkunaraj ah, M. et al., Assessment of ocular transduction using -stranded and
self-complementary recombinant adeno-associated virus serotype 2/8, Gene Ther. 15,
7 (2008).
Choi, V. W. et al., AAV hybrid serotypes: improved vectors for gene delivery, Curr.
Gene Ther., 5, 299-310 (2005).
Wu, Z. et al., Adeno—associated virus serotypes: vector toolkit for human gene
therapy, Mol. Ther., 14, 316—327 .
Chuong, AS. et al., Non-invasive l inhibition with a red-shifted microbial
rhodopsin, Nat Neurosci, 17, 1123-1129 (2014).
Claims (14)
1. Use of an adeno-associated virus (AAV) vector comprising a nucleic acid encoding a gene product that is sensitive and/or that modulates nous light-sensitive 5 signalling in a photoreceptor cell, in the manufacture of a medicament for improving vision in a patient with cone photoreceptor dysfunction and/or degeneration by introduction of said nucleic acid into healthy rod photoreceptors in the retina of the patient and expression of said gene product therein, such that the range of light intensities to which the rod photoreceptor responds is extended and/or the speed at which the rod photoreceptor 10 ds to light is increased, wherein the gene product is ArchT or R9AP; and the capsid of the AAV vector is derived from AAV8. 15
2. Use of an AAV vector according to claim 1, wherein the genome of the AAV vector is d from AAV2.
3. Use of an AAV vector according to claim 1 or 2, wherein the patient suffers from macular degeneration, achromatopsia or Leber congenital amaurosis.
4. Use of an AAV vector according to claim 3, wherein the macular degeneration is age-related macular degeneration (AMD), an inherited macular degeneration condition or an inherited cone dystrophy. 25
5. Use of an AAV vector according to claim 4, wherein the AMD is wet or neovascular AMD or geographic atrophy.
6. Use of an AAV vector according to any one of the ing claims, wherein rod eceptor signalling is extended into the mesopic and/or photopic illumination range.
7. Use of an AAV vector according to any one of the ing claims, n the rods exhibit improved modulation strength and/or faster activation/inactivation kinetics.
8. Use of an AAV vector according to any one of the preceding , wherein the medicament is intended to be introduced into rod photoreceptors in vitro and transplanted into the retina.
9. Use of an AAV vector according to any one of the preceding claims, wherein the mesopic and/or photopic vision of the patient is improved.
10. Use of an AAV vector according to any one of the preceding claims, wherein the 10 nucleic acid is intended to be expressed under the control of a photoreceptor-specific or photoreceptor-preferred promoter.
11. Use of an AAV vector according to claim 10, wherein said photoreceptor-specific or photoreceptor-preferred promoter is a rod-specific or rod-preferred promoter.
12. Use of an AAV vector according to any one of claims 1 to 11, wherein the nucleic acid is intended to be expressed under the control of a rod-specific promoter.
13. Use of an AAV vector according to any one of claims 10 to 12, wherein the nucleic 20 acid is intended to be expressed under the l of a sin (Rho), Neural retinaspecific leucine zipper protein (NRL) or Phosphodiesterase 6B (PDE6B) promoter.
14. Use of an AAV vector ing to any one of claims 1 to 13 wherein the medicament is intended to be used in ation with another therapy.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201503008A GB201503008D0 (en) | 2015-02-23 | 2015-02-23 | Treatment |
GB1503008.3 | 2015-02-23 | ||
PCT/GB2016/050419 WO2016135457A1 (en) | 2015-02-23 | 2016-02-19 | Gene therapy to improve vision |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ735735A NZ735735A (en) | 2021-09-24 |
NZ735735B2 true NZ735735B2 (en) | 2022-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9968689B2 (en) | AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells | |
US8470790B2 (en) | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids | |
US11969478B2 (en) | Optimized RPE65 promoter and coding sequences | |
KR20200103634A (en) | A method of expressing a polynucleotide of interest in a subject's conical photoreceptor comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-inducing vector | |
AU2022201553A1 (en) | Gene therapy to improve vision | |
US20220047655A1 (en) | Aav-mediated gene transfer for retinopathy | |
NZ735735B2 (en) | Gene therapy to improve vision | |
VISION | Gene Therapy To Improve Vision | |
EA042590B1 (en) | GENE THERAPY FOR IMPROVED VISION | |
Khabou | Development of safe and efficient aav vectors for retinal gene therapy | |
WO2024033837A1 (en) | Human cone photoreceptor optogenetic constructs | |
WO2023023256A1 (en) | Aav-mediated gene transfer for retinopathy | |
JP2021520231A (en) | Compositions and methods for the treatment of Stargart's disease | |
Kolstad | Development and assessment of gene therapies for inherited blinding diseases |